An emerging company is focused on the development of the best-in-class immunotherapy technology for cancer cure. Teamed up with outstanding immunologists and molecular biologists, the firm has generated a strong pipeline of Chimeric Antigen Receptor (CAR) product candidates to treat a wide variety of liquid and solid tumors. Legend Biotech is a subsidiary company of a large Chinese CRO. The firm is actively seeking investment, partnering and licensing opportunities to expand the pipeline of therapeutics and offerings. Typical allocations are $1-10 M.

The firm’s sectors of focus are cell and gene therapies, cell engineering, processing and manufacturing technologies and tools.

The firm may seek a board seat depending upon size of investment. They are open to working with all stages of management teams. The firm can either lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharma/biotech investment arm of a Middle East-based family office with a total AUM of $1B through its four investment arms is actively seeking investment opportunities. The firm is stage-agnostic, however the firm is fundamentally science-driven and considers mainly early pre-clinical and clinical-stage projects, preferably with POC validation. The firm’s investment size ranges widely from $0.5M – $20M and comes in the form of straight equity. The firm seeks board representation and is a very active investor, helping guide the company’s development and strategy. The firm invests globally and may lead investments, but typically co-invests in U.S.-based companies. The firm has no targeted number of investments per year.

The firm has also recently started an accelerator program with several globally established companies for pre-seed investments in early stage assets, including tech transfer from universities. This program provides $1-1.5M in funding for two years to help companies achieve POC and be ready to raise a Series A round. The program is open to technologies developed globally that are willing to be advanced in the country the investment firm is based in.

The firm is open to both pre-clinical and clinical stage companies and is agnostic to technology type and indication. The firm has a specific interest in immuno-oncology, gene therapy and orphan or unmet medical need. The firm is only interested in first-in-class, breakthrough assets and does not consider re-purposed assets or iterative technologies. The accelerator program is focused on therapeutics in oncology, immuno-oncology, immunology, fertility, endocrinology, gene therapy, synthetic biology and microbiome-related technologies.

The firm prefers to invest early and help take the company through a major inflection point. The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused, evergreen incubator fund based in the USA is now focusing on orphan drugs and rare diseases via a holding company-fund business model pioneered by the firm in 2009 for common diseases. The firm collaborates with an affiliate on projects that are not in the orphan diseases space.

The firm has a high threshold for working with companies and makes most of its investments in companies with which there is some type of relationship, but it is open to new opportunities as well on a case-by-case basis. The firm is mainly focused on therapeutics and will consider platform technologies that are therapeutic focused e.g. digital therapeutics. The firm’s investment size varies widely depending on the needs of the company. The capital structure depends on the financing round, with convertible notes being preferred for seed rounds and equity for everything else (no debt financing) with the preferred entry point being seed or Series A.

The firm only co-invests, and does not lead rounds unless the key principals are part of founding entrepreneurs. The firm has some limitations on geographic exposure and will consider companies in the United States, Canada, Singapore, Australia, Hong Kong, Spain, the Netherlands or the United Kingdom.

The firm will invest in therapeutics (no specific indication) that treats orphan diseases with strong scientific rationale. For the firm, not all orphan indications are rare or ultra-rare since the future is fragmentation of common indications characterized through genomics or proteomics profile. The firm is interested in clinical stage assets starting from Phase IIa but on a case by case basis earlier stage assets that are validated in pre-clinical models.

In the past, the firm has invested in therapeutics (a single asset or a company with multiple products), which treat unmet needs in glaucoma, thrombosis (in particular patients with prosthetic heart valves and renal dysfunction), atrial fibrillation, inflammatory disorders (such as ulcerative colitis), gastrointestinal disorders (such as constipation, reflux disease) as well as a small molecule to treat neurovascular disorders such as Alzheimer’s disease, wet-age related macular degeneration.

The firm will consider clinical-stage therapeutics (or with those with other therapeutic modalities) to treat orphan disease including small molecules, and novel biologics (including “biobetters”) that are likely to obtain or already have issued composition of matter patents (and/or method of use patents) and platform technologies (that could generate novel drug candidates for orphan diseases), repurposed drugs with issued IP, biosimilars and digital therapeutics. The firm has interest in diagnostics, medical devices (for drug-device combination only) or digital health (data analytics for diagnosing diseases) as long as the focus is on orphan diseases. Any areas outside these, the firm collaborates with an affiliate to enable set-up and/or growth.

The firm does not have any specific management team requirements, and will work with all entrepreneurs. A board seat is not always required, but is not uncommon.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech company founded in 2016 with several offices in China is VC backed with $150M Series A funding followed by $260 MM Series B funding. With immuno-oncology as the firm’s core therapeutic focus, the company strives to lead Chinese research to the global market through its world class R&D team, its innovative portfolio, and an open innovation strategy. The company has a rich developing pipeline of oncology assets and is currently seeking in-licensing and partnership opportunities globally. The firm can invest in both private and public companies, depending on development stage of assets. The firm’s investment size depends on applicable deals.

The firm is particularly interested in first in class, truly innovative oncology assets from pre-clinical to market except for CAR-T therapy. The firm is currently focused on opportunities for the greater China market.

The firm’s team is flexible and is open to working with all different kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Eastern USA makes initial investments from $5-$15M with $35M over the lifetime of the company. The firm invests globally and has particular experience with partners located in the United States, Israel, and the United Kingdom.

The firm seeks early-stage nanotechnology and stem cell research, particularly in cancer, therapeutic and regenerative medicine. The firm is primarily interested in clinical stage Ph I/II technology. The firm focuses their expertise in regenerative and therapeutic medicine, with a focus on stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. Specific to oncology, the firm is interested in novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

The firm requires management teams with experience in the field. The firm seeks board representation post-investment and remains actively supportive with portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm with offices in USA and China is focused on medical device technologies. The firm is formed by pharmaceutical and medical device industry veterans and high-net-worth individuals with a committed capital of US$40 million. Typical investment size ranges from US $500K – 5 million. The firm is open to leading or following in a financing round. Since 2016, the firm has begun broadening its geographic exposure and is currently seeking seed to early-stage opportunities from the US, Canada, Israel, and China.

The firm is interested in unique, disruptive medical device technologies with a focus on the following target markets: ophthalmic diagnostic or therapeutic device; visual optics technology; home use and personal care device; in-vitro diagnostics (IVD); and surgical equipment and consumables. The firm considers products that have at least completed prototype and obtained in-vivo proof-of-concept.

The firm is looking for competent management teams with strong sector expertise. The firm can request board representation after investment on a case-by-case basis. The firm does not focus only on products with a China angle, however, it can aid in identifying strategic partners in the Chinese market. The firm has expertise in helping portfolio companies in China Strategy, market strategy, regulatory strategy, and exit strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital company with offices in Eastern USA is currently making investments from its vintage 2013 fund and is looking to make equity investments into early stage medical devices and digital health companies. The firm’s investment size varies depending on the financial needs of the company and they generally participate in seed through series B rounds. To date, the firm has only made investments in companies throughout the United States though they are open to pursuing investments globally. The firm generally makes 1-2 new investment per year.

The firm is focused entirely on early stage medical devices and digital health. The firm is open to invest in all classes of medical devices and all indications and all areas of digital health. The firm generally looks to be the first round of institutional financing often investing in companies that have yet to fully develop their prototype. Companies the firm has invested in previously include devices for Orthopedics, Diagnostics, DNA Sequencing, Women’s Health, Diabetes, Imaging, and Active and Implantable Devices.

The firm is looking for companies whose market has barriers to entry, a quick path to proof of concept, and capital efficient operations. The firm looks for passionate founders and will evaluate management on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.